Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kenvue Inc. Common Stock (KVUE) vs Smith & Nephew plc (SNN) Price & Performance

Kenvue Inc. Common StockTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Kenvue Inc. Common Stock vs Smith & Nephew plc — how do they compare? Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Kenvue Inc. Common Stock is far larger — about 3.1× Smith & Nephew plc's market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.74%). Which is the better fit depends on your goals.

KVUESNN
Market Cap
$34.06B$11.10B
Volume
23,267,2281,051,703
Sector
Consumer StaplesHealth
52-Week High
$19.83$37.17
52-Week Low
$14.11$26.42
Enterprise Value
$41.56B$14.13B
Dividend Yield
4.74%2.95%
Typical Hold Time
—121 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kenvue Inc. Common Stock

No Aura AI signal available yet.

Smith & Nephew plc

Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.

The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kenvue Inc. Common Stock

Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.

Read more on KVUE →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →